For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

Oxytocin: origin, structure and research history

Research Library › Neuropeptides

Oxytocin is a naturally occurring nine-amino-acid peptide hormone, with a ring closed by a disulfide bond, that is released from the posterior pituitary gland. Its biological activity was first noted in pituitary extracts by Henry Dale in 1906, and Vincent du Vigneaud’s group determined its structure and synthesized it in 1953. As of October 2026, synthetic oxytocin is an FDA-approved prescription drug sold under the brand name Pitocin, among others.

Key facts

TypeEndogenous cyclic nonapeptide hormone (nine amino acids, one disulfide bridge, amidated C-terminus)
Molecular formulaC43H66N12O12S2 (molecular weight about 1007)
First described1906, uterine-contracting activity of posterior pituitary extract reported by Henry Dale; named in 1928
Developed byStructure determined and first synthesized by Vincent du Vigneaud and colleagues, Cornell University Medical College, 1953
Designed targetOxytocin receptor, a G protein-coupled receptor (human gene cloned in 1992)
Regulatory status (Oct 2026)FDA-approved prescription drug (Pitocin, NDA 018261) with labeled obstetric indications; boxed warning against elective induction of labor

Who developed it

Oxytocin is made by the body, so its history is one of discovery rather than invention. In 1906 the British physiologist Henry Dale, working at the Wellcome Physiological Research Laboratories, reported that extracts of the posterior pituitary gland caused the uterus to contract [1].

In 1928 Oliver Kamm and colleagues at Parke, Davis and Company separated two distinct active principles from posterior pituitary extract and named them oxytocin and vasopressin [2]. The name comes from Greek words meaning “swift birth.”

The decisive chemical work came from Vincent du Vigneaud’s laboratory, which worked out the amino acid sequence and reported the first laboratory synthesis of the hormone in 1953 [3]. Du Vigneaud received the 1955 Nobel Prize in Chemistry, in part for this first synthesis of a polypeptide hormone [4].

Structure and design

Oxytocin is a nonapeptide: a chain of nine amino acids. Two cysteine residues, at positions 1 and 6, are joined by a disulfide bond, which closes the first six residues into a ring and leaves a short three-residue tail ending in an amide group [3, 7]. Du Vigneaud’s 1953 paper described it as an octapeptide amide because the two linked cysteines were counted as a single cystine unit [3].

The molecule is closely related to vasopressin, from which it differs at two positions [7]. Its molecular formula is C43H66N12O12S2, with a molecular weight of roughly 1007 [7].

Oxytocin’s natural binding partner is the oxytocin receptor, a G protein-coupled receptor. Kimura and colleagues reported the cloning and structure of the human oxytocin receptor in 1992 [5].

Research history

  • 1906: Dale reports uterine-contracting activity of posterior pituitary extract [1]
  • 1928: Kamm and colleagues separate and name oxytocin and vasopressin [2]
  • 1953: Du Vigneaud’s group reports the structure and first synthesis [3]
  • 1955: Du Vigneaud awarded the Nobel Prize in Chemistry [4]
  • 1980: Original approval date of the current Pitocin application, NDA 018261, in FDA records [6]
  • 1992: Human oxytocin receptor cloned [5]

The 1953 synthesis was a landmark in peptide chemistry. It showed for the first time that a hormone made in the laboratory could match the natural substance, and it opened the way to synthetic peptide drugs.

Regulatory status as of October 2026

Synthetic oxytocin is an FDA-approved prescription drug. FDA records list Pitocin (oxytocin injection) under NDA 018261, with an original approval date of 19 November 1980 for that application [6]. The label covers obstetric indications related to inducing or strengthening uterine contractions when medically indicated and to the period after delivery [7].

The Pitocin label carries a boxed warning stating that the drug is not indicated for elective induction of labor, meaning induction without a medical reason [7]. Approval of the injectable product does not extend to other forms, routes or uses, and products sold for research use only are not approved drugs.

About this reference page

Kalibra Labs does not currently supply Oxytocin. This page is published as a neutral scientific and regulatory reference. Browse the Neuropeptides guide or the FDA Peptide Regulatory Tracker.

Frequently asked questions

Who discovered oxytocin?

Henry Dale first reported the uterine-contracting activity of posterior pituitary extract in 1906. Oliver Kamm’s group named oxytocin in 1928, and Vincent du Vigneaud’s group determined its structure and synthesized it in 1953 [1, 2, 3].

How many amino acids are in oxytocin?

Oxytocin has nine amino acids, two of which are cysteines joined by a disulfide bond that forms a ring [3, 7].

Is oxytocin FDA approved?

Yes. Synthetic oxytocin injection is FDA-approved, for example as Pitocin under NDA 018261, for labeled obstetric indications. The label states it is not indicated for elective induction of labor [6, 7].

Why did du Vigneaud win the Nobel Prize?

The 1955 Nobel Prize in Chemistry recognized his work on biochemically important sulfur compounds, especially the first synthesis of a polypeptide hormone, which was oxytocin [4].

How is oxytocin related to vasopressin?

Both are nine-amino-acid hormones of the posterior pituitary with a similar ring structure. They differ at two amino acid positions [2, 7].

Sources

  1. Dale HH. On some physiological actions of ergot. J Physiol. 1906;34(3):163–206. Link
  2. Kamm O, Aldrich TB, Grote IW, Rowe LW, Bugbee EP. The active principles of the posterior lobe of the pituitary gland. I. The demonstration of the presence of two active principles. II. The separation of the two principles and their concentration in the form of potent solid preparations. J Am Chem Soc. 1928;50:573–601. Link
  3. du Vigneaud V, Ressler C, Swan JM, Roberts CW, Katsoyannis PG, Gordon S. The synthesis of an octapeptide amide with the hormonal activity of oxytocin. J Am Chem Soc. 1953;75(19):4879–4880. Link
  4. The Nobel Prize in Chemistry 1955: Vincent du Vigneaud, facts. NobelPrize.org. Link
  5. Kimura T, Tanizawa O, Mori K, Brownstein MJ, Okayama H. Structure and expression of a human oxytocin receptor. Nature. 1992;356:526–529. Link
  6. U.S. FDA. Drugs@FDA: Pitocin (oxytocin injection), NDA 018261, application overview. Link
  7. Pitocin (oxytocin injection, USP) synthetic, prescribing information (Par Health), including boxed warning and description. Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

Kalibra Labs does not supply this compound. This page is a scientific, historical and regulatory reference only; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top